Spring Bank Pharmaceuticals Financing
Spring Bank Pharmaceuticals, Inc., Corporation just filed form D announcing $15.00 million equity financing. This is a new filing. Spring Bank Pharmaceuticals was able to sell $15.00 million. That is 100.00% of the fundraising offer. The total financing amount was $15.00 million. The offering form was filed on 2016-11-23. The reason for the financing was: unspecified.
Spring Bank Pharmaceuticals is based in Massachusetts. The filler’s business is Biotechnology. The SEC form was submitted by Jonathan Freve Chief Financial Officer. The company was incorporated more than five years ago. The filler’s address is: 86 South Street, Hopkinton, Ma, Massachusetts, 01748. Martin Driscoll is the related person in the form and it has address: 86 South Street, Hopkinton, Ma, Massachusetts, 01748. Link to Spring Bank Pharmaceuticals Filing: 000156637316000008.
Analysis of Spring Bank Pharmaceuticals Offering
On average, companies in the Biotechnology sector, sell 73.77% of the total offering size. Spring Bank Pharmaceuticals sold 100.00% of the offering. Could this mean that the trust in Spring Bank Pharmaceuticals is high? The average investment offering size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 387.01% bigger than the average for companies in the Biotechnology sector. The minimum investment for this financing was set at $0. If you know more about the reasons for the financing, please comment below.
What is Form D? What It Is Used For
Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.
Why Fundraising Reporting Is Good For Spring Bank Pharmaceuticals Also
The Form D signed by Jonathan Freve might help Spring Bank Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.